Kalbe Farma Tbk PT banner

Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 870 IDR -1.69% Market Closed
Market Cap: Rp40.7T

EV/IC

1.5
Current
49%
Cheaper
vs 3-y average of 2.9

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.5
=
Enterprise Value
Rp39.9T
/
Invested Capital
Rp23.8T

Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.

EV/IC
1.5
=
Enterprise Value
Rp39.9T
/
Invested Capital
Rp23.8T

Valuation Scenarios

Kalbe Farma Tbk PT is trading below its 3-year average

If EV/IC returns to its 3-Year Average (2.9), the stock would be worth Rp1 695.77 (95% upside from current price).

Statistics
Positive Scenarios
3/4
Maximum Downside
-52%
Maximum Upside
+127%
Average Upside
54%
Scenario EV/IC Value Implied Price Upside/Downside
Current Multiple 1.5 Rp870
0%
3-Year Average 2.9 Rp1 695.77
+95%
5-Year Average 3.4 Rp1 977.34
+127%
Industry Average 2.1 Rp1 264.44
+45%
Country Average 0.7 Rp416.61
-52%

Forward EV/IC
Today’s price vs future invested capital

Not enough data available to calculate forward EV/IC

Peer Comparison

All Multiples
EV/IC
P/E
All Countries
Close

Market Distribution

Higher than 71% of companies in Indonesia
Percentile
71th
Based on 861 companies
71th percentile
1.5
Low
0 — 0.3
Typical Range
0.3 — 1.4
High
1.4 —
Distribution Statistics
Indonesia
Min 0
30th Percentile 0.3
Median 0.7
70th Percentile 1.4
Max 115 637.5

Kalbe Farma Tbk PT
Glance View

Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.

KLBF Intrinsic Value
1 375.51 IDR
Undervaluation 37%
Intrinsic Value
Price Rp870
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett